Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2019-11-22 Legal Proceedings Report
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science provides clarification regarding the article published yesterday in the newspaper Les Echos related to the investigation by the French market authorities
Legal Proceedings Report Classification · 1% confidence The document is a short press release dated November 22, 2019, clarifying a newspaper article regarding an ongoing investigation by the French market authorities (AMF). It discusses the investigation, references prior disclosures in the annual financial report, and provides general company information and forward-looking statements. It is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific announcement concerning legal/regulatory matters (the AMF investigation) and is brief, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory/legal update that doesn't match other specific codes like LTR (Legal Proceedings Report, which usually details the proceedings themselves rather than a company response to media coverage about them) or DIRS/DIV/etc. Given its nature as a company statement responding to regulatory news, RNS is the most appropriate general regulatory fallback.
2019-11-22 English
AB Science annonce des résultats de phase 3 positifs du masitinib dans l’asthme sévère
Earnings Release Classification · 1% confidence The document is a press release dated November 7, 2019, announcing positive Phase 3 results for the drug masitinib in severe asthma. It details the primary endpoint achievement (p=0.0103), safety profile comparison with placebo, quotes from investigators, and future plans (presentation at a scientific congress, another Phase 3 study results expected in H1 2020). This format—a timely announcement of key clinical trial results and financial/operational updates—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses specifically on announcing the *results* of a clinical trial, it aligns best with the 'Earnings Release' category (ER), which often covers key operational milestones and financial outcomes, even if not strictly quarterly earnings. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available. Given the context of a major clinical trial result announcement, ER is the most appropriate fit among the provided options for a significant operational/results announcement. Q4 2019
2019-11-07 French
AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
Earnings Release Classification · 1% confidence The document is a press release dated November 7, 2019, announcing 'positive top-line Phase 3 results for oral masitinib in severe asthma.' It details clinical trial endpoints, safety data, and future plans (webcast, results presentation). This content strongly aligns with an Earnings Release (ER) which typically announces key periodic financial or operational results, or an Investor Presentation (IP) if it were a slide deck. However, the structure—a formal announcement of study results, including statistical significance and adverse events—is characteristic of an Earnings Release or a specific operational update that functions similarly to an ER by providing key performance indicators (clinical trial success in this case). Since it is a direct announcement of a major operational milestone (Phase 3 success) rather than a comprehensive financial report (10-K or IR), and it is not a transcript (CT) or a general regulatory filing (RNS), the best fit among the provided options is Earnings Release (ER), as it communicates the period's most significant operational outcome. Q4 2019
2019-11-07 English
AB Science annonce que la molécule AB8939 obtient la désignation de médicament orphelin auprès de la FDA dans le traitement de la leucémie myéloïde aigue
Regulatory Filings Classification · 1% confidence The document is a press release dated November 7, 2019, announcing that the molecule AB8939 has received Orphan Drug Designation from the US FDA for the treatment of acute myeloid leukemia. This type of announcement, detailing a specific regulatory milestone (Orphan Drug Designation) and its implications (commercial exclusivity, funding opportunities), is characteristic of an Earnings Release (ER) or a general regulatory/corporate update. Since it is a specific, time-sensitive announcement of a regulatory event rather than a comprehensive financial report (10-K, IR) or a transcript (CT), it fits best under the 'Earnings Release' category if it's a major corporate event announcement, or potentially 'Regulatory Filings' (RNS) if it were less detailed. Given the structure (headline announcement, details on the designation, background on the disease, company boilerplate, forward-looking statements), it functions as a significant corporate news release, which often overlaps with ERs when they contain material, non-financial operational news. However, none of the definitions perfectly capture 'Regulatory Milestone Announcement' outside of the general 'RNS'. Since it is a formal announcement of a significant corporate development (FDA designation), and not a quarterly financial summary (ER) or a general filing notice (RPA/RNS), I will evaluate the closest fit. It is not a financial report, a management change, or a dividend notice. It is a specific regulatory/development update. In many databases, such specific, material announcements are classified as Earnings Releases (ER) if they are issued outside of scheduled financial reporting periods, or RNS if they are purely regulatory disclosures. Given the context of financial reporting databases, major corporate news releases often fall under ER if they are material. However, the content is purely regulatory/developmental. Let's re-examine the options. It is not a 10-K, AR, IR, or MRQ. It is not a CTA or DIV. It is a specific regulatory event announcement. Since 'Regulatory Filings' (RNS) is the fallback for miscellaneous filings that don't fit, and this is a specific regulatory event announcement, RNS is a strong candidate. However, the 'Earnings Release' (ER) definition is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, the most appropriate category for a specific, material, non-financial regulatory/development announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS). I will select RNS as the best fit for a specific regulatory milestone announcement not covered by other specific codes.
2019-11-07 French
AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
Regulatory Filings Classification · 1% confidence The document is a press release dated November 7, 2019, announcing that AB Science SA received Orphan Drug Designation from the FDA for compound AB8939 for treating acute myeloid leukemia (AML). This type of announcement, detailing a specific regulatory event (FDA designation) and its implications (exclusivity, funding), is a general corporate update. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a specific shareholder/director transaction report. Since it is a significant, non-standard regulatory/development update that doesn't fit the more specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official announcements not covered elsewhere, or potentially a general Investor Relations communication. Given the nature of the announcement (FDA action), RNS is the most appropriate general regulatory filing category.
2019-11-07 English
AB Science annonce la première présentation de résultats précliniques de la molécule AB8939 au 61eme congrès annuel de l'American Society of Hematology (ASH)
Regulatory Filings Classification · 1% confidence The document is a press release dated November 6, 2019, announcing that AB Science will present preclinical results for its molecule AB8939 at the 61st annual congress of the American Society of Hematology (ASH). This is an announcement about scientific data presentation at a conference, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It details scientific findings and future clinical plans. Since it is an announcement related to company activities, research, and investor interest, but doesn't fit the specific categories like ER, CT, or IP (which are usually more formal presentations or transcripts), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Investor Presentation' (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the nature of announcing scientific progress and conference participation, RNS serves as the most appropriate general regulatory/corporate announcement fallback when specific scientific/research report codes are absent or inappropriate. However, since it is a specific announcement about research results being presented, it is a form of corporate communication aimed at investors and the public. Given the options, RNS is the best fit for a general corporate/regulatory announcement that isn't a core financial report or a formal presentation document.
2019-11-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.